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In this report, inhibitors of the g-secretase en-
zyme have been exploited to characterize the
antiproliferative relationship between target in-
hibition and cellular responses in Notch-depen-
dent human T cell acute lymphoblastic leukemia
(T-ALL) cell lines. Inhibition ofg-secretase led to
decreased Notch signaling, measured by en-
dogenous NOTCH intracellular domain (NICD)
formation, and was associated with decreased
cell viability. Flow cytometry revealed that de-
creased cell viability resulted from a G0/G1 cell
cycle block, which correlated strongly to the in-
duction of apoptosis. These effects associated
with inhibitor treatment were rescued by exoge-
nous expression of NICD and were not mirrored
when a markedly less active enantiomer was
used, demonstrating the g-secretase depen-
dency and specificity of these responses. To-
gether, these data strengthen the rationale for
using g-secretase inhibitors therapeutically
and suggest that programmed cell death may
contribute to reduction of tumor burden in the
clinic.
INTRODUCTION
In multicellular organisms, the Notch pathway [1–3] partic-
ipates in diverse fundamental processes, including cell-
fate decisions during development and tissue renewalChemistry & Biology 14, 209and repair in the adult. Both positive and negative Notch
pathway modulators act on a core signaling cascade [4],
in which extracellular ligand binding activates the recep-
tor, which, in turn, stimulates its sequential cleavage by
the proteases TNF-a converting enzyme (TACE) and g-
secretase to finally release the NOTCH intracellular do-
main (NICD). Once released from the membrane-bound
receptor, the cytosolic NICD polypeptide then translo-
cates to the nucleus to modulate transcription of down-
stream genes and, subsequently, cell growth [5, 6].
Increased Notch signaling has been associated with tu-
morigenesis [7–9], and NOTCH1 was first discovered via
a chromosomal translocation found in a small subset of
T cell acute lymphoblastic leukemias (T-ALL) [10]. Subse-
quently, enforced NOTCH1 signaling has been shown
both to act as a potent inducer of T-ALL in mice and to
sustain the growth of a human T-ALL cell line [11, 12]. In
addition, constitutively active mutants of the NOTCH fam-
ily have been associated with a range of cancers, includ-
ing some mammary and mucoepidermoid carcinomas
[13–16]. In other cancers, increased expression of NOTCH
wild-type family members leads to greater flux through the
Notch signaling pathway. For example, some lymphopro-
liferative cancers show increased expression of normal
NOTCH pathway members without evidence of associ-
ated mutations [17, 18]. An analogous increase in pathway
flux has been associated with50% of human breast can-
cers, on account of reduced expression of the NOTCH in-
hibitor Numb [19]. Also, a novel animal model suggests
that increased Notch signaling may also be associated
with medulloblastomas [20].
Consequently, inhibitors of g-secretase, originally de-
veloped as a potential treatment for Alzheimer’s disease,
may prevent NOTCH receptor cleavage [21–23] and–219, February 2007 ª2007 Elsevier Ltd All rights reserved 209
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Notch Inhibition Induces ApoptosisTable 1. Structures and Calculated Potencies for MRK-003 and MRK-006
MRK-003 MRK-006
Structure
SH-SY5Y SPA4CT cells 0.4 nM (0.08) 110.5 nM (2.56)
HEK NOTCHDE/APP cells 0.52 nM versus Ab (40) –
0.72 nM versus NICD –
Data in parentheses represent standard errors of the mean.provide an effective cancer therapy [24]. Although trans-
locations originally associated with T-ALL are extremely
rare [25], affecting less than 1% of the T-ALL population,
two recent reports strengthened the rationale for g-secre-
tase inhibition as a viable intervention in this disease. First,
it has been confirmed that some truncations that
remove a large portion of the NOTCH receptor ectodo-
main and result in ligand-independent signaling can re-
main membrane-associated and therefore dependent on
g-secretase for release of the NICD signaling fragment
[26]. Second, extensive sequencing has indicated that
56% of human T-ALL cases encode novel activating mu-
tations that enhance either NICD production or stability
[27]. The therapeutic potential of g-secretase inhibitors
for treating Notch-related T-ALL cases is therefore greater
than originally suggested by the rarity of the original chro-
mosomal translocations.
Despite these findings, important questions relating to
the downstream results of g-secretase inhibition remained
unanswered. In this study, we used a novel and extremely
potent g-secretase inhibitor from the recently disclosed
cyclic sulfamide structural series [28] as a chemical tool.
This has enabled us to decipher the consequences of
cell cycle arrest in representative human T-ALL cell lines
(HPB-ALL and DND-41) and to investigate its relationship
to the induction of apoptosis.
RESULTS
g-Secretase Inhibitors Used in This Study
In order to explore further the role of Notch signaling in
T-ALL, two novel g-secretase inhibitors were employed
(Table 1). MRK-003, initially developed from a screening
hit [28], is a cyclic sulfamide g-secretase inhibitor structur-
ally distinct from molecules such as DAPT (N-[N-(3,5-
difluorophenacetyl)-L-alanyl]-(S)-phenylglycine t-butyl es-
ter) [29] and the benzodiazepine Compound E [30].
MRK-003 is a potent g-secretase inhibitor with a subnano-
molar in vitro potency for the inhibition of Ab secretion210 Chemistry & Biology 14, 209–219, February 2007 ª2007 Efrom human neuroblastoma cells. It has been shown to
reduce brain Ab production in vivo after oral dosing of
mice [28]. In contrast, MRK-006 is its less active enantio-
mer and was selected as a negative control in order to
differentiate specific mechanism-based activity from idio-
syncratic effects. MRK-003 was characterized along with
a selection of over 50 inhibitors for its in vitro effects on the
cleavage of APP and the Notch receptor in HEK293 cells
[31]. In this system, MRK-003 inhibited the g-secretase-
mediated cleavage of the Notch receptor with essentially
the same potency as that of APP (Table 1).
MRK-003, a Potent g-Secretase Inhibitor, Decreases
T-ALL Cell Viability
Three T-ALL cell lines (DND-41, HPB-ALL, and TALL-1)
previously identified as being dependent on g-secretase
for proliferation [27] were chosen to evaluate the effects
of the g-secretase inhibitor MRK-003 on cell viability.
The HPB-ALL cell line demonstrated a time-dependent
decrease in cell viability between day 3 and day 8 after
incubation with inhibitor, with a highly potent effective
dose (ED50 9 nM) observed at day 8. MRK-006 was shown
to be far less effective at inhibiting viability in the same ex-
periment (Table 2). Inhibition of proliferation by MRK-003
was also recorded in the two additional T cell lines, with
DND-41 being less responsive than either HPB-ALL or
TALL-1 cells (Table 3). Clearly, exposure to MRK-003
leads to a marked decrease in measurable metabolic
activity of multiple T-ALL cell lines, indicative of a decrease
in cell viability/proliferation.
Dosage- and Time-Dependent Cell Cycle Arrest with
MRK-003
In order to investigate further the cause of the decreased
viability, treated cells were fixed and their DNA was la-
beled with propidium iodide, followed by FACS analysis.
This method allows the assignment of cell cycle popula-
tions according to their DNA content. HPB-ALL cells,
which are derived from a patient with T-ALL, were chosenlsevier Ltd All rights reserved
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work. As shown in Figure 1A, 10 mM MRK-003 led to
a marked arrest in cell cycle progression after 7 days, as
characterized by loss of cells in G2 and S phases and an
accumulation of cells in G1. This is in agreement with the
mechanism of G0/G1 cell cycle arrest seen with an alterna-
tive g-secretase inhibitor (Compound E) reported previ-
ously [27]. It is noteworthy that the inhibitor treatment
also appears to increase the abundance of the sub-G1
population, which suggests DNA fragmentation as a result
of apoptosis.
The time dependence of the G0/G1 cell cycle arrest is
shown by analysis of cultures incubated with increasing
concentrations of MRK-003 for 2, 3, 4, 5, and 6 days. As
shown by the representative histograms in Figure 1B
and by the plotted G2-S populations in Figure 1C, the
time required for arrest to be manifested depends to
some extent on the concentration of the inhibitor. How-
ever, the top doses begin to cause arrest after about 3
days, and a maximal effect is seen after 5–6 days. For
this reason, 7 days was selected as the incubation time
for subsequent studies.
A comprehensive titration of the effect of MRK-003 on
cell cycle arrest after 7 days is shown in Figure 2A. Analy-
sis of MRK-003 between 10 mM and 10 nM shows a grad-
ual loss of cell cycle arrest as levels of inhibitor are re-
duced. Nonlinear regression analysis allows the ED50 for
this inhibition to be estimated as 400 nM (Figure 2B).
Apoptosis Documented by FACS Analysis
Since a transient arrest of the cell cycle in tumor cells
would result in only a temporary cytostatic delay in
growth, it is vitally important to understand the fate of
the arrested cells. In particular, for any future therapeutic
application we wanted to investigate whether pro-
grammed cell death is a potential outcome of this pheno-
type. To this end, cells were incubated with inhibitor as de-
scribed above for 7 days and then collected for labeling
with FITC-labeled Annexin V. FACS analysis of vehicle-
treated cultures indicated that all cells showed only low
(or no) surface staining with this protein since its binding
partner, phosphatidylserine, is normally an asymmetric
resident of the inner membrane. However, in cells that
Table 2. Calculated Potencies for Inhibition of Cellular
Proliferation by MRK-003 and MRK-006 in HPB-ALL
Cells
Cell Viability ED50 (mM)
Day MRK-003 MRK-006 MRK-003/-006
3 3.300 11.7 4
6 0.060 4.7 78
8 0.009 5.2 578
Cells were incubated with compound as described in Experi-
mental Procedures. Data indicate the potencies for inhibition
of proliferation in HPB-ALL cells at three time points. Individ-
ual potencies for each compound, in addition to a ratiometric
comparison, are given.Chemistry & Biology 14, 209–had been treated with MRK-003, but not MRK-006, this
asymmetric distribution is lost, and a second population
with increased Annexin V staining can be detected (Fig-
ure 3). This population is likely to be an early indicator of
apoptosis rather than of late-stage necrosis since it is
not also associated with a general increase in cell perme-
ability to DNA staining (data not shown). Supporting the
observation of apoptosis, an increase in the sub-G1 pop-
ulations (e.g., Figure 1A) is also seen in parallel with the
Annexin V staining effects, although this effect was slightly
less robust between experiments.
We were able to titrate out this effect with lower doses of
inhibitor and estimate ED50s for the changes to the high-
and low-staining Annexin V peaks (and the ratio of the
two). In contrast, no apoptosis was seen in cells that
had insufficiently efficacious doses of MRK-003, in cells
not incubated for enough time, or in cell lines reported
not to depend on g-secretase for proliferation (data not
shown).
Correlations between Cell Cycle Arrest and
Induction of Apoptosis
Because the apoptosis analysis (Figure 3) was conducted
on cells incubated in parallel with those that underwent
analysis of cell cycle arrest (Figure 2), we were able to
compare the potencies and correlate the two processes.
As shown in Figure 3C, excellent correlations between in-
terference with cell cycle progression and the induction of
apoptosis after g-secretase inhibition are generated,
whether the changes in the low- or high-staining Annexin
V peak (or a ratio of the two) are compared. The ED50s
for the observed changes in cell cycle (400 nM; Figure 2B)
and apoptotic populations (440 nM) also show good
agreement (Figure 3D).
g-Secretase Inhibition Leads to Notch Receptor
Signaling
To verify that g-secretase inhibition led to loss of Notch
signaling in T cells, we sought to detect endogenous levels
of the NICD cleavage product in HPB-ALL cells. As shown
in Figure 4, lysates from HPB-ALL cells showed specific
labeling of a NICD band with a MW of 85 kDa, in
good agreement with the expected mass for full-length
Table 3. Comparative Potencies for Inhibition of
Cellular Proliferation by MRK-003 and MRK-006 in
Different T-ALL Cell Lines
Cell Viability ED50 (mM)
Cell Line MRK-003 MRK-006 MRK-003/-006
HPB-ALL 0.009 5.2 578
TALL-1 <0.005 2.3 >460
DND-41 0.320 13.0 41
Cells were incubated with compound as described in Experi-
mental Procedures. Data indicate the potencies for inhibition
of proliferation at day 8 in three cell lines. Individual potencies
for each compound, in addition to a ratiometric comparison,
are given.219, February 2007 ª2007 Elsevier Ltd All rights reserved 211
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Notch Inhibition Induces ApoptosisFigure 2. Dose Responsiveness of Cell Cycle Arrest
(A) Representative FACS traces indicate titration of cell cycle arrest seen at 7 days with MRK-003, but not MRK-006.
(B) The data are also plotted to estimate relative potencies. Note that error bars indicating standard error of the mean (SEM) are smaller than the
symbols on the graph.NICD, which disappeared upon incubation with MRK-003
at 10 mM. A gradual reappearance of this NICD band was
seen with decreasing doses of inhibitor. Lysates from cells
overexpressing the NOTCHDE construct (included as a
positive control) led to the detection of a band with a
slightly lower molecular weight, consistent with the re-
ported deletion of the C-terminal PEST sequence from
this construct in order to enhance NICD stability [32]. Incu-
bation with a comprehensive range of concentrationsChemistry & Biology 14, 209allows an ED50 for NICD generation to be estimated to
be 30 nM by densitometry.
Rescue of Antiproliferative and Proapoptotic Effects
of g-Secretase Inhibition by Expression of NOTCH
Intracellular Domain
In order to confirm that the observed effects of the g-sec-
retase inhibitor MRK-003 on cell cycle arrest and induc-
tion of apoptosis are solely mediated through inhibitionFigure 1. Demonstration of Cell Cycle Arrest after g-Secretase Inhibition
(A and B) Representative FACS histogram traces indicate the (A) extent and (B) timing of cell cycle arrest.
(C) The time course data (single point) are tabulated more fully.–219, February 2007 ª2007 Elsevier Ltd All rights reserved 213
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Notch Inhibition Induces ApoptosisFigure 3. Dose Responsiveness of Apoptosis
(A) Representative FACS traces indicate titration of cell cycle arrest seen at 7 days with MRK-003, but not MRK-006.
(B) The data are also shown in bar charts in order to quantify the changes in the low- and high-staining Annexin V peaks, as well as a ratio of the two.
Induction of apoptosis generally leads to the appearance of a population (labeled ‘‘HIGH’’) that stains well for Annexin V in parallel with a loss of cells
from the unstained (‘‘LOW’’) group. Camptothecin (6 mM, 24 hr) is included as a positive control. Error bars represent SEM.
(C and D) Comparative correlations and potencies for effects of MRK-003 on cell cycle arrest and apoptosis are shown. Error bars represent SEM.of Notch signaling, and not via the cleavage of other
substrates [33, 34], the ability of NICD expression to
overcome these phenomena was examined. As shown
in Figure 5, DND-41 cells (previously shown to be respon-
sive to g-secretase inhibition in Table 1) lose the ability to
undergo both G0/G1 arrest and apoptosis in response to
MRK-003 (1 mM) if infected with a retrovirus encoding
NICD, in contrast to cells containing the empty vector
control construct (MigR1).
DISCUSSION
The ability of g-secretase inhibitors to induce cell cycle ar-
rest and apoptosis in human T-ALL cell lines strengthens
the rationale for their use in the treatment of cancer.
Cell cycle block, induction of apoptosis, and specificity
observed through the NICD rescue experiment, as well
as cycle arrest observed with human T-ALL cell lines,214 Chemistry & Biology 14, 209–219, February 2007 ª2007 Elagree with studies conducted with an alternative g-secre-
tase inhibitor (Compound E) in the engineered murine T6E
cell line [35] and demonstrate that the cyclic sulfamide
structural series, specifically MRK-003, is a useful tool
for studying g-secretase inhibition and Notch pathway
modulation. In T-ALL cells, MRK-003 blocked cell cycle
progression and decreased cellular metabolism in a pro-
cess that became apparent after a few days. Closer exam-
ination of the affected populations indicates that they ex-
hibit a marked loss of cells in G2 and S phases of the cell
cycle and an accumulation of cells in G0/G1. The efficacy
of MRK-003 has been well studied in a number of cell lines
in vitro, but, to our knowledge, this is the first published
report to demonstrate, by western blotting, an ability to
inhibit the processing of endogenous Notch receptor in
a T cell line. The degree of g-secretase inhibition, directly
monitored by inhibition of Notch receptor processing, cor-
related well with cell cycle arrest and apoptosis. Evidencesevier Ltd All rights reserved
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Notch Inhibition Induces ApoptosisFigure 4. Demonstration of Endogenous NICD in HPB-ALL and Inhibition by MRK-003
HPB-ALL cells were incubated with MRK-003 for 48 hr, and the cells were collected, lysed, and solubilized as described. Levels of NICD were
detected by western blot relative to b-tubulin as a loading control.of apoptosis, monitored by flow cytometry analysis with
FITC-conjugated Annexin V, was supported further by ev-
idence of DNA fragmentation, represented by sub-G0/G1
populations. This correlation suggests that cell death is
an irrevocable result of the cell cycle disruption triggered
by g-secretase inhibition in T-ALL cells. Finally, exoge-
nous expression of active NICD in a T-ALL cell line and
the concomitant loss of responsiveness to MRK-003
clearly demonstrate that both cell cycle arrest and apo-
ptosis are absolutely dependent on Notch signaling,
which, in turn, can be pharmacologically modulated with
g-secretase inhibitors.Chemistry & Biology 14, 209–2Our studies help explain a number of recent reports
that link g-secretase inhibition to antiproliferative effects
in T cell lines [27, 35], cell and animal models of melanoma
[36], and lung cancer cell lines overexpressing NOTCH3
[37]. Similarly, reports consistent with the model of g-
secretase inhibitor-mediated induction of apoptosis are
also beginning to emerge. For example, apoptosis is
reported to follow g-secretase inhibition in T cells [35], in
lung cell lines [37], in Kaposi’s sarcoma tumor cells [39],
and in medulloblastoma xenografts [20]. Activated Notch
signaling has been linked to inhibition of apoptosis in
Hodgkin’s and anaplastic large-cell lymphoma [18], inFigure 5. Overexpression of the Intracellular Domain of NOTCH1, NICD, Rescues the Cell Cycle Block and Apoptosis Induction of
Treating T-ALL Cells with MRK-003
(A–E) DND-41 cells infected with either MigR1 (empty vector) or MigR1 NICD were treated with 1 mM MRK-003 for 7 days. The effects on the cell cycle
and apoptosis induction were assessed by flow cytometry. Error bars indicate SEM.19, February 2007 ª2007 Elsevier Ltd All rights reserved 215
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Notch Inhibition Induces Apoptosispapillomavirus-induced cervical cancer [38], and in mye-
loma [40]. Also consistent with this model are data
suggesting that the NOTCH1 and lactation-dependent
mammary tumors regress initially at weaning due to apo-
ptosis, but that this response is substantially reduced as
the tumors progress toward invasive adenocarcinomas
[41]. An interesting report of Notch signaling conversely
inducing apoptosis in neural progenitor cells may be
indicative of contrary networks of Notch signaling and/or
apoptosis at this distinct developmental stage [42].
Although these reports document antiproliferative and
proapoptotic effects of g-secretase inhibition, these phe-
nomena have seldom been addressed simultaneously
prior to this report. These studies confirm induction of
cell cycle arrest in g-secretase-sensitive human T-ALL
cell lines [27] and expand previous findings by demon-
strating parallel induction of apoptosis in the selected
cell lines. The correlation between arrest and apoptosis
demonstrated here by using HPB-ALL cells (Figure 3C)
is both novel, to our knowledge, and extremely strong
and has also been reproduced in another T-ALL cell line
(DND-41) after exposure to g-secretase inhibitors (data
not shown). Our work benefits from the ability to assess
both read-outs from parallel treatments in the same exper-
iments. Additionally, the dose-response curves employed
allow for accurate estimation of the potencies for the
incidence of both phenomena. Of note, some published
apoptosis studies in Kaposi’s sarcoma cells [39] and B
cell chronic lymphocytic leukemia [43] may be partially
confounded by the use of compounds like Z-Leu-Leu-
Nle-CHO that have broad specificity against other prote-
ases such as the proteasome. The work in this report is
also strengthened by exploiting the potent and specific
inhibitor MRK-003, plus its far less active enantiomer,
and extends its use as a sound research tool.
The finding that NICD expression is able to rescue
DND-41 from undergoing cell cycle arrest and apoptosis
strongly suggests that loss of Notch signaling is the most
critical result of g-secretase inhibition, despite the growing
list of proteins that are proposed to be additional sub-
strates of this enzyme complex [33, 34]. Taken together,
these biological data complement and fully support the
conclusions from the g-secretase inhibitor studies. To
our knowledge, the ability to quantify endogenous NOTCH
receptor cleavage in cultured T cell lines also provides
a novel means for investigating the effects of g-secretase
inhibition. Previous studies have usually relied on in-
creased levels from overexpressed polypeptides in order
to demonstrate genetic or pharmacological efficacy
against Notch processing. Although our assay was rou-
tinely incubated for 2 days to maximize the magnitude of
the effect, NICD levels were also substantially reduced af-
ter treatment with g-secretase inhibitors for 24 hr, a time
frame consistent with cleavage effects on other Notch
assays [31]. That incubations of 4–7 days are routinely
required for antiproliferative effects to become manifest
implies that increased time might be required for the action
of g-secretase inhibitors to be transmitted from Notch to
cooperating cell cycle interactors.216 Chemistry & Biology 14, 209–219, February 2007 ª2007 ElsThe growing list of such partners proposed to interact
with Notch to stimulate oncogenesis includes regulators
such as C-MYC [44], E2A-PBX1 [45], and IKAROS [46],
plus many common oncoproteins, including adenovirus
E1A [47], HPV E6 and E7 [48, 49], RAS [50], and SV40T
[51]; it will be interesting to discover the downstream nu-
ances of how Notch directly impacts proliferation path-
ways. Additionally, the disconnect between the potencies
for inhibition of Notch cleavage and the potency for effects
on cell cycle/apoptosis is similarly indicative of additional
inputs into the proliferation cycle that would benefit from
further study. Mechanistic studies in myeloma systems
suggest that Notch signaling influences apoptosis via ef-
fects on p53 in some [38, 42], but not all [52], cases, and
mediators like p21 [40, 52] and phosphorylated AKT [37,
52] may also be involved in Notch-mediated oncogenesis.
It is highly likely, however, that these associations, like
most Notch pathway effects, will prove to be subject to
complex temporal and spatial regulation dependent on
the cellular context in question.
In conclusion, we demonstrate that a potent, specific g-
secretase inhibitor is able to cause both cell cycle arrest
and, in parallel, induce apoptosis through a Notch-depen-
dent mechanism in cells originated from T-ALL patients.
These processes correlate extremely well, suggesting
that g-secretase inhibitor-induced apoptosis might con-
tribute to the reduction of Notch-related tumor burden in
vivo. Given that Notch signaling has been linked to can-
cers of the breast [19], colon [53], lung [54], pancreas
[55], and prostate [56], as well as to gliomas [57], medullo-
blastomas [20], and mesotheliomas [51], it will be interest-
ing to ascertain whether this general model will have
similar therapeutic benefits for other tumor types.
SIGNIFICANCE
Growing evidence supports the use of inhibitors of
Notch signaling for therapeutic intervention against
a number of cancers linked with increased Notch
activity. This work strengthens the rationale for thera-
peutic intervention by further characterizing the
antiproliferative mechanisms using newly disclosed,
potent inhibitors as chemical tools in immortalized
T-ALL lines. Clear cessation of cell growth and block-
age of cell cycle progression (at G0/G1) are reproduc-
ibly observed in a time-, dose-, and Notch signaling-
dependent manner. This finding highlights a strong
connection between cell cycle arrest and induction
of apoptosis when both phenomena are measured in
parallel after inhibition with a g-secretase inhibitor.
The excellent correlation between these processes
supports the possibility that inhibition of g-secretase
might contribute substantially to the reduction of tu-
mor burden, as well to arrested proliferation, in the
clinic. The loss of endogenous NOTCH cleavage prod-
uct in T cells with increasing doses of g-secretase
inhibitor and the lack of inhibitor responsiveness
observed with exogenous overexpression of NICD
also support the Notch-dependent phenotype of theseevier Ltd All rights reserved
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Notch Inhibition Induces Apoptosiscompounds. Futurework isneeded toconfirmwhether
apoptosis correlates with cell cycle arrest in other
cancers associated with increased Notch signaling.
EXPERIMENTAL PROCEDURES
Compounds
MRK-003 and MRK-006, described previously [28], were synthesized
according to standard medicinal chemistry procedures. Stocks at
10 mM in DMSO were used for the dilutions described in this study.
Both positive control treatments, paclitaxel and camptothecin, were
sourced from Sigma Aldrich Fluka.
Proliferation Assays
HPB-ALL, DND-41, and TALL-1 cell lines were seeded to 96-well
plates (1.0 3 104 cells in 90 ml/well) in media specified by the cell line
supplier (DSMZ, German National Resource Centre for Biological Ma-
terial) that contained 10% FBS. After overnight incubation of 90 ml at
37C in 5% CO2, 10 ml media containing 103 g-secretase inhibitor
stock was added, yielding a final concentration of 0.1% DMSO, and
cells were resuspended by gentle pipetting. Media containing inhibitor
(75 ml) were replaced after a brief centrifugation every 2 days, and the
cells were completely resuspended. Cell viability was measured after
8 days of treatment by using ATPlite (PerkinElmer, Wellesley, MA)
according to the manufacturer’s instructions.
Quantification of Cell Cycle Arrest by FACS
HPB-ALL cells were seeded at a density of 0.63 106 in 1 ml in 24-well
plates with RPMI media containing 10% FBS and were cultured for 7
days with g-secretase inhibitor (10 mM and lower). Compound levels
were replenished, and the cells were split (usually 2-fold), so as to
remain in the supplier’s recommended linear growth range, on days
2 and 4. At the end of the incubation, the cells were pelleted by brief
centrifugation, resuspended in PBS, and fixed in 70% ethanol on ice
for up to 2 hr. The fixed cells were then stained with 20 mg/ml propidium
iodide in a PBS buffer that also contained 0.1% Triton X-100 and
0.2 mg/ml RNase. Labeled cell cycle populations were quantified by
using a Fluorescence Activated Cell Sorting (FACS) Canto instrument
from Beckton Dickenson (Franklin Lakes, NJ). Wells previously incu-
bated with 4–6 mM paclitaxel (which caused G2/M block due to stabi-
lization of microtubules) for 24 hr were included as positive controls.
Quantification of Apoptosis by FACS
Cells were incubated with inhibitors and were split exactly as de-
scribed in the preceding section. At the end of the incubation, the cells
were collected, and any increase in apoptosis was assessed by using
the Annexin V staining kit from BD Biosciences (#556547) according to
manufacturer’s instructions. Phosphatidylserine, which binds Annexin
V, is usually located only on the inner leaflet of the plasma membrane in
cells. Loss of this asymmetry and increased staining for Annexin V on
the outer membrane are early indicators of apoptosis. Briefly, cells are
labeled with FITC-labeled Annexin V, and changes in cell populations
stained by this antibody are recorded by FACS. Lack of accessible nu-
cleic acid staining by propidium iodide under the kit buffer conditions is
used in parallel to rule out any whole-scale loss of membrane integrity
reported in necrosis. Wells incubated with 6 mM camptothecin for 24 hr
were included as positive controls for induction of apoptosis.
Western Blot Analysis of Notch Receptor Processing/NICD
Generation
HPB-ALL cells were cultured at 43 106 cells in 3 ml media in 3 cm di-
ameter dishes with the specified g-secretase inhibitors from DMSO
stocks (at 10003 concentrations) and were incubated for 48 hr at
37C in 5% CO2. The cells were harvested, washed with PBS, and
lysed in 50 ml lysis buffer (50 mM Tris [pH 7.4] containing 150 mM so-
dium chloride, 1% Triton X-100, 0.5% NP-40, and 0.2% SDS). After
gentle agitation for 25 min at 4C, lysates were centrifuged for 10Chemistry & Biology 14, 209–21min at 14,000 3 g, and the protein concentration of the supernatant
was determined by using BCA reagent (Pierce, Rockford, IL) with bo-
vine serum albumin as a standard. Equal amounts of protein (30 mg)
were loaded and separated on 10%–20% Tricine gels (Novex) prior
to transfer onto nitrocellulose membranes. The membranes were
blocked for 2 hr in phosphate-buffered saline (PBS) containing 10%
skim milk powder (Merck, Darmstadt, Germany). The blots were then
probed with anti-cleaved NOTCH1 Val-1744 antibody (Cat #2421,
Cell Signaling Technologies, Danvers, MA) for 2 hr at 1:400 in PBS, fol-
lowed by PBS washes (five washes for 5 min/wash) and incubation
with the secondary antibody, HRP-conjugated donkey anti-rabbit
(GE Healthcare, Bucks, UK), for 1 hr at room temperature at 1:5,000
in PBS. Proteins from washed membranes were visualized by using
ECL reagent from Amersham. Parallel detection with b-tubulin anti-
body (Sigma, #T5293) was used to provide a loading control.
Virus Production and T-ALL Cell Line Infection
HEK293T cells were transfected with either the empty vector (MigR1)
or with a vector encoding the intracellular form of NOTCH1 (MigR1
NICD) along with pKatAmpho and pCMV-VSV-G by using Lipofect-
amine PLUS (Invitrogen). Viral supernatants were removed 60 hr later,
were filtered, and were used to infect DND-41 cells in the presence of
polybrene. Infected cells were collected by flow sorting of GFP+ cells.
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